12 months ago
Neuland Labs Stock: Up 5,500% in Five Years, Brokerage Initiates Coverage
Imagine a company called Neuland Labs that makes things for other companies in the medicine world.
They are doing very well!
Over five years, the price of their stock has gone way, way up.
Now, a financial company called Nuvama thinks Neuland Labs will keep growing a lot.
They predict the company's revenue will increase a lot by the year 2028.
The company is expanding its facilities, which helps in their predicted growth.
Big investors like Vijay Kedia and Mukul Agrawal own shares.
Nuvama recommends people buy the stock, expecting its price to rise even further, but warns of potential risks.
Nuvama initiated coverage on Neuland Laboratories, a pharma stock.
The company's revenue is projected to grow 1.8 times from FY25 to FY28.
Neuland stock has increased over 5,540% in the last five years.
The stock is trading at 39x FY27E EPS, with Nuvama valuing it at 44x Sep-27E EPS.
Key shareholders include Mukul Agrawal and Vijay Kedia.
- Who
- Neuland Laboratories, brokerage firms Nuvama and B&K Securities.
- What
- Nuvama initiated coverage on Neuland Laboratories, projecting significant growth for the company.
- Where
- N/A
- When
- Coverage initiated recently, stock performance over past five years.
- Why
- Due to anticipated growth in the complex contract manufacturing sector, particularly the CMS segment.
Key facts
- Company
- Neuland Laboratories
- Founded
- 1984
- Stock Price (Thursday Close)
- Rs 14,605.60
- 52-Week High
- Rs 18,089.55 (December 2024)
- Shareholders
- Vijay Kedia, Mukul Agrawal, Mutual Funds, Domestic Insurance Companies
- Nuvama Target Price
- Rs 17,700
- B&K Securities Target Price
- Rs 16,000
Quotes
B&K Securities
An investment firm
“Overall, we remain on positive on Neuland due to its strong ongoing capex programmes for future growth plus plans to acquire additional land at Unit 1 for future capacity expansion and healthy CMS pipeline with 98 molecules at various stages of development”
businesstoday.in
